Dr Yang Meng PhD (Warwick)

Research Fellow                                                                                                                                                       meng1

HEDS, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA

Tel: (+44) (0)114 222 0673
Fax: (+44) (0)114 272 4095

E-mail: y.meng@sheffield.ac.uk

Biography

I joined the HEDS section of ScHARR in March 2009 after graduating with a PhD in Operational Research (Simulation Modelling) from the University of Warwick in 2009.
I am currently working as a healthcare modeller in the Health Economics and Decision Science (HEDS) section of ScHARR. I am also a member of the Sheffield Alcohol Research Group (SARG).

Research interests

  • Decision modelling on alcohol and other public health policy interventions
  • Cost-effectiveness and healthcare modelling
  • Agent-based simulation and discrete-event simulation

Teaching interests

I teach two modules for the MSc Health Economics and Decision Science (MSc HEDM): Advanced Simulation Methods (HAR672) and Operational Research Techniques in Health Resource Allocation (HAR671).

PhD supervision

  • Eunju Kim: Modelling Sequential Drug Decision Problems in Long-term Medical Conditions using Discrete Event Simulation: a Case Study of Primary Hypertension

I am interested in supervising PhD Research Students in topics/areas including public health policy appraisal and evaluation using decision modelling, econometric analysis of the demand for alcohol/tobacco and products which are potentially detrimental to health, and general cost-effectiveness modelling and cost-effectiveness modelling.

Professional activities

I am a member of the Sheffield Alcohol Research Group.

Grants and awards:

  • Co-investigator of the “Evidence-based model for estimating requirements for specialist alcohol treatment capacity in England ”, funded by the Department of Health
  • Co-investigator of the “Studying Alcohol Pricing Policies and Developing a Model for Alcohol Control through Research and Evidence Based Advocacy in India”, funded by International Development Research Centre
  • Co-investigator of the “Second Update to the Scottish Adaptation of the Sheffield Alcohol Policy Model", funded by the Scottish Government
  • Co-investigator of the “Update to the Scottish Adaptation of the Sheffield Alcohol Policy Model”, funded by the Scottish Government

I recently worked on the following projects:

  • Modelling the impact of pricing and promotion polices for alcohol in Scotland (funded by the Scottish government)
  • Cost-effectiveness modelling of Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (funded by NICE MTA programme)
  • Economical evaluation of the use of positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in breast cancer (funded by NHS R&D HTA programme)
  • Modelling to assess the effectiveness and cost-effectiveness of public health related strategies and interventions to reduce alcohol attributable harm in England (funded by NICE)
  • The effectiveness of rapid screening tests on reducing MRSA transmission in the hospital setting (funded by the Department of Health)

Current projects

  • Interdisciplinary alcohol policy effectiveness research programme (funded by MRC/ESRC)
  • Evidence-based model for estimating requirements for specialist alcohol treatment capacity in England (funded by Department of Health)

Key publications

  • Meng Y, Brennan A, Purshouse R, Hill-McManus D, Angus C, et al. Estimation of own and cross price elasticities of alcohol demand in the UK – a pseudo-panel approach using the Living Costs and Food Survey 2001 to 2009. Journal of Health Economics 2014 34: 96-103.
  • Holmes J, Meng Y, Meier P, Brennan A, Angus C, et al. Minimum unit pricing for alcohol: policy appraisal modelling of income and socioeconomic group-specific effects on consumption, spending, and health harms. Lancet (http://dx.doi.org/10.1016/S0140-6736(13)62417-4).
  • Brennan A, Meier P, Purshouse R, Rafia R, Meng Y, et al. Developing policy analytics for public health strategy and decisions - the Sheffield alcohol policy model framework. Annals of Operational Research 2013 (DOI: 10.1007/s10479-013-1451-z).
  • Hill-McManus D, Angus C, Meng Y, Holmes J, Brennan A, et al. Estimation of usual occasion-based individual drinking patterns using diary survey data. Drug and Alcohol Dependence 2013 134: 136-143.
  • Meng Y, Brennan A, Holmes J, Hill-McManus D, Angus C, et al. Modelled income group-specific impacts of alcohol minimum unit pricing in England 2014/15: Policy appraisals using new developments to the Sheffield Alcohol Policy Model (v2.5). Sheffield Alcohol Research Group Website 2013 (http://www.shef.ac.uk/polopoly_fs/1.291621!/file/julyreport.pdf)
  • Meng Y, Holmes J, Hill-Mcmanus D, Brennan A, Meier P. Trend analysis and modelling of gender specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in Great Britain using the General Lifestyle Survey 1984-2009. Addiction 2013 109(2): 206-215.
  • Meier P, Meng Y, Holmes J, Baumberg B, Pursehouse R, et al. Adjusting for unrecorded consumption in survey and per capita sales data: Quantification of impact on gender- and age-specific alcohol attributable fractions for liver cirrhosis in Great Britain. Alcohol and Alcoholism 2013 48(2): 241-249.
  • Meng Y, Squire H, Stevens J, Simpson E, Harnan S, et al. Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology 2013 65(3): 190-197.
  • Squires H, Simpson E, Meng Y, Harnan S, Stevens JW, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment 15(40):i-210 2011.
  • Meng Y, Hill-McManus D, Brennan A, Meier P. Model-based appraisal of alcohol minimum pricing and off-licensed trade discount bans in Scotland using the Sheffield Alcohol Policy Model (v.2): Second update based on newly available data. http://www.shef.ac.uk/polopoly_fs/1.156503!/file/scotlandjan.pdf.
  • Meng Y, Ward S, Cooper K, Harnan S, Wyld L. Cost-effectiveness of MRI and PET for the evaluation of axillary lymph node metastases in early stage breast cancer. European Journal of Surgical Oncology 2011 37(1):40-46.
  • Cooper K, Meng Y, Harnan S, Ward S, Fitzgerald P, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in breast cancer: systematic review and economic evaluation. Health Technology Assessment 2011 15(4):iii-134.
  • Meng Y, Davies R, Hardy K, Hawkey P. The application of agent-based simulation to the modelling of MRSA transmission in hospital. Journal of Simulation 2010 4(1):60-67.
  • Purshouse P, Brennan A, Latimer N, Meng Y, Rafia R, et al. Modelling to assess the effectiveness and cost-effectiveness of public health related strategies and interventions to reduce alcohol attributable harm in England using the Sheffield Alcohol Policy Model version 2.0. http://www.nice.org.uk/guidance/index.jsp?action=download&o=45668.